{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:41:02Z","timestamp":1778024462241,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1395,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>There is need for an evidence\u2010based comparison of clinical management strategies to provide the rationale for selection of a particular therapeutic approach to treatment. Ideal dyspepsia treatment should quickly and conveniently alleviate patient symptoms whilst also minimizing the use of healthcare resources.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To examine dyspepsia symptom relief over 16\u2003weeks and compare an omeprazole clinical management strategy with a commonly used combination of antacid\u2013alginate followed by H<jats:sub>2<\/jats:sub>\u2010antagonist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Seven hundred and twenty\u2010five patients participated in this randomized, open, parallel group comparison over 16\u2003weeks. Patients were randomized to receive either an omeprazole treatment strategy (363) consisting of omeprazole 10\u2003mg stepping up to 20\u2003mg and 40\u2003mg as required, or an antacid\u2013alginate\/ranitidine treatment strategy (362) consisting of antacid\u2013alginate 10\u2003mL q.d.s. stepping up to ranitidine 150\u2003mg b.d. and 150\u2003mg q.d.s. as required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A greater proportion of patients receiving the omeprazole clinical management strategy had achieved the stringent health target of complete symptom relief (61 vs. 40%, <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001) at 16\u2003weeks. Forty\u2010six per cent of omeprazole\u2010treated patients were symptom free after the first 10\u2003mg step compared to only 17% in the antacid\u2013alginate treated group (<jats:italic>P<\/jats:italic>\u2003=\u20030.0001). Total relief of heartburn, the most common symptom at entry, was achieved by more patients in the omeprazole treatment group than the antacid\u2013alginate\/ranitidine treatment group, 62 vs. 36%, respectively, at 4 weeks, and 81 vs. 60% at 16 weeks (<jats:italic>P<\/jats:italic>\u2003=\u20030.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Treatment with the omeprazole clinical management strategy was superior to the antacid\u2013alginate\/ranitidine management strategy in providing relief of acid\u2010related dyspepsia symptoms after 16 weeks. In addition, the omeprazole treatment strategy involved fewer GP consultations and thus minimized the use of other healthcare resources.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.00282.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:36:14Z","timestamp":1047353774000},"page":"263-271","source":"Crossref","is-referenced-by-count":39,"title":["The management of acid\u2010related dyspepsia in general practice: a comparison of an omeprazole versus an antacid\u2010alginate\/ranitidine management strategy"],"prefix":"10.1111","volume":"12","author":[{"family":"Mason","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Millar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Turbitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.4.401"},{"key":"e_1_2_6_3_2","first-page":"47","article-title":"Prevalence of symptoms of dyspepsia in the community","volume":"1","author":"Jones R","year":"1989","journal-title":"Lancet"},{"key":"e_1_2_6_4_2","first-page":"1136","article-title":"Endoscopic studies of dyspepsia in general practice","volume":"1","author":"Gear MWL","year":"1989","journal-title":"Br Med J"},{"key":"e_1_2_6_5_2","first-page":"6","article-title":"Upper gastrointestinal endoscopy\u2014a view from general practice","volume":"36","author":"Jones R","year":"1986","journal-title":"R Coll Gen Pract"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90879-3"},{"key":"e_1_2_6_7_2","unstructured":"CheshireM.Patient outcomes a new agenda. Clinician in management.1995;4(5)."},{"key":"e_1_2_6_8_2","unstructured":"NHS Executive. Promoting clinical effectiveness: A framework for action in and throughout the NHS. Crown Copyright1996."},{"key":"e_1_2_6_9_2","unstructured":"FeltonA&ListerG. Consider the Evidence The NHS on the Move Towards Evidence Based Medicine. Uxbridge: Coopers and Lybrand 1996."},{"key":"e_1_2_6_10_2","unstructured":"ForresterE.Alternative advice on dyspepsia treatment.Gasto\u2010renterol Pract1994; Feb\/Mar: 6\u20137."},{"key":"e_1_2_6_11_2","first-page":"39","article-title":"Dyspepsia: GP guide to drug management","volume":"19","author":"Heatley R","year":"1995","journal-title":"Prescriber"},{"key":"e_1_2_6_12_2","first-page":"52","article-title":"Dyspepsia: A rational approach to management","volume":"19","author":"Crompton B","year":"1995","journal-title":"Prescriber"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92023-0"},{"key":"e_1_2_6_14_2","first-page":"293","article-title":"Dyspepsia: Is a trial of therapy appropriate?","volume":"153","author":"Thompson G","year":"1995","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_15_2","first-page":"119","article-title":"Cost\u2010effective management of dyspepsia","volume":"10","author":"Mucklow JC","year":"1996","journal-title":"Br J Med Econ"},{"key":"e_1_2_6_16_2","unstructured":"British Society of Gastroenterology. Guidelines in Gastroenterology 1; Dyspepsia Management Guidelines. September1996."},{"key":"e_1_2_6_17_2","volume":"37","author":"Venables T","year":"1995","journal-title":"Gut"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.4.492"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00532.x"},{"key":"e_1_2_6_20_2","article-title":"First line treatment with omeprazole 10\u2003mg om is a more effective strategy than Gaviscon 10\u2003mL qid in the relief of dyspepsia symptoms in primary care","volume":"39","author":"Goves J","year":"1996","journal-title":"Gut"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6138.653"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00282.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00282.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1998.00282.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:07:56Z","timestamp":1698462476000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.00282.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1046\/j.1365-2036.1998.00282.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.00282.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}